APC alterations in papillary thyroid carcinoma: molecular mechanisms, clinical implications, and future perspective

Azin Soltani1, Farideh Razi2, Alireza Abdollahi3

  • 1Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Insights

The adenomatous polyposis coli (APC) gene, a tumor suppressor, plays a role in papillary thyroid carcinoma (PTC) development. APC alterations may offer diagnostic and therapeutic insights for PTC, particularly in familial cases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, driven by MAPK signaling.
  • Emerging evidence implicates Wnt/β-catenin signaling pathway dysregulation in thyroid tumor development.
  • The adenomatous polyposis coli (APC) gene, a tumor suppressor, is crucial in regulating β-catenin and has been linked to FAP-associated thyroid carcinoma.

Purpose of the Study:

  • To review the structure, function, and role of the APC gene in Wnt/β-catenin signaling and PTC pathogenesis.
  • To discuss the contribution of germline and somatic APC alterations to FAP-associated thyroid tumors.
  • To explore the diagnostic, prognostic, and therapeutic implications of APC alterations in PTC.

Main Methods:

  • Literature review summarizing existing research on APC gene function and its role in thyroid cancer.
  • Analysis of molecular mechanisms linking APC dysregulation to thyroid carcinogenesis.
  • Discussion of clinical implications including molecular testing, precision medicine, and surveillance.

Main Results:

  • APC gene negatively regulates β-catenin, and its alterations are implicated in thyroid tumor development and progression.
  • Germline and somatic APC alterations contribute to FAP-associated thyroid tumors.
  • While uncommon in sporadic PTC, APC abnormalities may influence tumor progression and aggressive subtypes, potentially holding clinical value with other markers.

Conclusions:

  • APC gene alterations are relevant to PTC pathogenesis, especially in familial cases.
  • APC mutations may have diagnostic, prognostic, and therapeutic implications, aiding precision medicine and genetic counseling.
  • Further translational studies are needed to fully understand the clinical significance of APC mutations in PTC.

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cellular Adaptation IV: Dysplasia and Metaplasia01:24

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...